AU2013342321B2 - Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment - Google Patents

Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment Download PDF

Info

Publication number
AU2013342321B2
AU2013342321B2 AU2013342321A AU2013342321A AU2013342321B2 AU 2013342321 B2 AU2013342321 B2 AU 2013342321B2 AU 2013342321 A AU2013342321 A AU 2013342321A AU 2013342321 A AU2013342321 A AU 2013342321A AU 2013342321 B2 AU2013342321 B2 AU 2013342321B2
Authority
AU
Australia
Prior art keywords
long
liquid formulation
oxyntomodulin derivative
lasting
lasting oxyntomodulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013342321A
Other languages
English (en)
Other versions
AU2013342321A1 (en
Inventor
Sung Min Bae
Myung Hyun Jang
Hyun Uk Kim
Sang Yun Kim
Se Chang Kwon
Hyung Kyu Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of AU2013342321A1 publication Critical patent/AU2013342321A1/en
Application granted granted Critical
Publication of AU2013342321B2 publication Critical patent/AU2013342321B2/en
Priority to AU2017279583A priority Critical patent/AU2017279583B2/en
Priority to AU2020200626A priority patent/AU2020200626B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2013342321A 2012-11-06 2013-11-06 Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment Active AU2013342321B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017279583A AU2017279583B2 (en) 2012-11-06 2017-12-18 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment
AU2020200626A AU2020200626B2 (en) 2012-11-06 2020-01-29 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20120124725 2012-11-06
KR10-2012-0124725 2012-11-06
PCT/KR2013/009986 WO2014073842A1 (en) 2012-11-06 2013-11-06 Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017279583A Division AU2017279583B2 (en) 2012-11-06 2017-12-18 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment

Publications (2)

Publication Number Publication Date
AU2013342321A1 AU2013342321A1 (en) 2015-05-28
AU2013342321B2 true AU2013342321B2 (en) 2017-09-28

Family

ID=50684883

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013342321A Active AU2013342321B2 (en) 2012-11-06 2013-11-06 Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
AU2017279583A Active AU2017279583B2 (en) 2012-11-06 2017-12-18 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment
AU2020200626A Active AU2020200626B2 (en) 2012-11-06 2020-01-29 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017279583A Active AU2017279583B2 (en) 2012-11-06 2017-12-18 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment
AU2020200626A Active AU2020200626B2 (en) 2012-11-06 2020-01-29 Liquid Formulation Of Protein Conjugate Comprising The Oxyntomodulin And An Immunoglobulin Fragment

Country Status (26)

Country Link
US (3) US9724420B2 (https=)
EP (2) EP3610856B1 (https=)
JP (2) JP6363612B2 (https=)
KR (2) KR102311517B1 (https=)
CN (1) CN104884045B (https=)
AR (2) AR093387A1 (https=)
AU (3) AU2013342321B2 (https=)
BR (1) BR112015010235B1 (https=)
CA (1) CA2890324C (https=)
CL (1) CL2015001206A1 (https=)
DK (1) DK2916819T3 (https=)
EA (3) EA034499B1 (https=)
ES (1) ES2748158T3 (https=)
IL (2) IL238626B (https=)
MX (2) MX372833B (https=)
MY (2) MY197849A (https=)
NZ (3) NZ708103A (https=)
PE (1) PE20151421A1 (https=)
PH (2) PH12018501454A1 (https=)
PL (1) PL2916819T3 (https=)
PT (1) PT2916819T (https=)
SG (2) SG11201503370WA (https=)
TW (3) TWI602583B (https=)
UA (2) UA116364C2 (https=)
WO (1) WO2014073842A1 (https=)
ZA (1) ZA201503998B (https=)

Families Citing this family (41)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
UA126465C2 (uk) 2011-06-10 2022-10-12 ะฅะฐะฝะผั– ะกะฐะนะตะฝั ะšะพ., ะ›ั‚ะด. ะŸะตะฟั‚ะธะด, ั‰ะพ ะผะฐั” ะฐะบั‚ะธะฒะฝั–ัั‚ัŒ ะพะบัะธะฝั‚ะพะผะพะดัƒะปั–ะฝัƒ, ั‚ะฐ ั„ะฐั€ะผะฐั†ะตะฒั‚ะธั‡ะฝะฐ ะบะพะผะฟะพะทะธั†ั–ั ะดะปั ะปั–ะบัƒะฒะฐะฝะฝั ะพะถะธั€ั–ะฝะฝั, ัะบะฐ ะนะพะณะพ ะผั–ัั‚ะธั‚ัŒ
RU2607365C2 (ru) 2011-06-17 2017-01-10 ะฅะฐะฝะผะธ ะกะฐะนะตะฝั ะšะพ., ะ›ั‚ะด. ะšะพะฝัŠัŽะณะฐั‚, ัะพะดะตั€ะถะฐั‰ะธะน ะพะบัะธะฝั‚ะพะผะพะดัƒะปะธะฝ ะธ ั„ั€ะฐะณะผะตะฝั‚ ะธะผะผัƒะฝะพะณะปะพะฑัƒะปะธะฝะฐ, ะธ ะตะณะพ ะฟั€ะธะผะตะฝะตะฝะธะต
KR20130049671A (ko) 2011-11-04 2013-05-14 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์ƒ๋ฆฌํ™œ์„ฑ ํด๋ฆฌํŽฉํƒ€์ด๋“œ ๊ฒฐํ•ฉ์ฒด ์ œ์กฐ ๋ฐฉ๋ฒ•
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101968344B1 (ko) * 2012-07-25 2019-04-12 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์˜ฅ์‹ ํ† ๋ชจ๋“ˆ๋ฆฐ ์œ ๋„์ฒด๋ฅผ ํฌํ•จํ•˜๋Š” ๊ณ ์ง€ํ˜ˆ์ฆ ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
UA116217C2 (uk) 2012-10-09 2018-02-26 ะกะฐะฝะพั„ั– ะŸะตะฟั‚ะธะดะฝะฐ ัะฟะพะปัƒะบะฐ ัะบ ะฟะพะดะฒั–ะนะฝะธะน ะฐะณะพะฝั–ัั‚ ั€ะตั†ะตะฟั‚ะพั€ั–ะฒ glp1-1 ั‚ะฐ ะณะปัŽะบะฐะณะพะฝัƒ
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) * 2012-11-06 2019-10-01 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์˜ฅ์‹ ํ† ๋ชจ๋“ˆ๋ฆฐ ์œ ๋„์ฒด๋ฅผ ํฌํ•จํ•˜๋Š” ๋‹น๋‡จ๋ณ‘ ๋˜๋Š” ๋น„๋งŒ์„ฑ ๋‹น๋‡จ๋ณ‘ ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
CR20160376A (es) 2014-01-20 2016-10-07 Hanmi Pharm Ind Co Ltd Insulina de acciรณn prolongada y uso de la misma
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteรญnas y pรฉptidos usando un enlace del fragmento fc de inmunoglobulina.
TW201625668A (zh) 2014-04-07 2016-07-16 ่ณฝ่ซพ่ฒๅ…ฌๅธ ไฝœ็‚บ่ƒœ่‚ฝๆ€ง้›™้‡๏ฝ‡๏ฝŒ๏ฝ๏ผ๏ผ‘๏ผๆ˜‡็ณ–็ด ๅ—้ซ”ๆฟ€ๅ‹•ๅŠ‘ไน‹่‰พๅกž้‚ฃ่‚ฝ๏ผ๏ผ”่ก็”Ÿ็‰ฉ
TW201625669A (zh) 2014-04-07 2016-07-16 ่ณฝ่ซพ่ฒๅ…ฌๅธ ่ก็”Ÿ่‡ช่‰พๅกž้‚ฃ่‚ฝ๏ผ๏ผ”๏ผˆ๏ผฅ๏ฝ˜๏ฝ…๏ฝŽ๏ฝ„๏ฝ‰๏ฝŽ๏ผ๏ผ”๏ผ‰ไน‹่‚ฝ้กž้›™้‡๏ผง๏ผฌ๏ผฐ๏ผ๏ผ‘๏ผๅ‡็ณ–็ด ๅ—้ซ”ไฟƒๆ•ˆๅŠ‘
TW201625670A (zh) 2014-04-07 2016-07-16 ่ณฝ่ซพ่ฒๅ…ฌๅธ ่ก็”Ÿ่‡ช๏ฝ…๏ฝ˜๏ฝ…๏ฝŽ๏ฝ„๏ฝ‰๏ฝŽ๏ผ๏ผ”ไน‹้›™้‡๏ฝ‡๏ฝŒ๏ฝ๏ผ๏ผ‘๏ผๅ‡็ณ–็ด ๅ—้ซ”ไฟƒๆ•ˆๅŠ‘
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composiciรณn para tratar diabetes que comprende conjugados de anรกlogos de insulina de acciรณn prolongada y conjugados de pรฉptidos insulinotrรณpicos de acciรณn prolongada
AR100695A1 (es) * 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composiciรณn para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagรณn
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 ๅ—้Ÿ“ๅ•†้Ÿ“็พŽ่—ฅๅ“่‚กไปฝๆœ‰้™ๅ…ฌๅธ ้•ทๆ•ˆglp-1/้ซ˜่ก€็ณ–็ด ๅ—้ซ”้›™ไฟƒๆ•ˆๅŠ‘ๆฒป็™‚้ž้…’็ฒพๆ€ง่„‚่‚็–พ็—…ไน‹็”จ้€”
CN112656939B (zh) * 2014-09-22 2023-12-08 ๆญฃๅคงๅคฉๆ™ด่ฏไธš้›†ๅ›ข่‚กไปฝๆœ‰้™ๅ…ฌๅธ ไธ€็ง้’ˆๅฏน่ก€็ฎกๅ†…็šฎ็”Ÿ้•ฟๅ› ๅญ็š„ไบบๆบๅŒ–ๆŠ—ไฝ“็š„่ฏ็‰ฉ็ป„ๅˆ็‰ฉ
PE20171154A1 (es) 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
KR102418477B1 (ko) 2014-12-30 2022-07-08 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ๊ธ€๋ฃจ์นด๊ณค ์œ ๋„์ฒด
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profรกrmacos que comprenden un conjugado agonista dual de glp-1 / glucagรณn conector รกcido hialurรณnico
EP4523705A3 (en) * 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (zh) 2015-07-10 2017-02-16 ่ณฝ่ซพ่ฒๅ…ฌๅธ ไฝœ็‚บ้ธๆ“‡ๆ€ง่‚ฝ้›™้‡๏ฝ‡๏ฝŒ๏ฝ๏ผ๏ผ‘๏ผๅ‡็ณ–็ด ๅ—้ซ”ไฟƒๆ•ˆๅŠ‘ไน‹ๆ–ฐๆฏ’่œฅๅค–ๆณŒ่‚ฝ๏ผˆ๏ฝ…๏ฝ˜๏ฝ…๏ฝŽ๏ฝ„๏ฝ‰๏ฝŽ๏ผ๏ผ”๏ผ‰่ก็”Ÿ็‰ฉ
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Anรกlogos de insulina novedosos
US10702606B2 (en) * 2015-12-10 2020-07-07 Menicon Co., Ltd. Peptide composition
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3479841A4 (en) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF
JP7158378B2 (ja) 2016-09-23 2022-10-21 ใƒใƒณใƒŸ ใƒ•ใ‚กใƒผใƒžใ‚ทใƒฅใƒผใƒ†ใ‚ฃใ‚ซใƒซ ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ใƒชใƒŸใƒ†ใƒƒใƒ‰ ใ‚คใƒณใ‚นใƒชใƒณๅ—ๅฎนไฝ“ใจใฎ็ตๅˆๅŠ›ใŒๆธ›ๅฐ‘ใ•ใ‚ŒใŸใ€ใ‚คใƒณใ‚นใƒชใƒณใ‚ขใƒŠใƒญใ‚ฐๅŠใณใใฎ็”จ้€”
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv ู…ุฑูƒุจุงุช ุจุจุชูŠุฏ ุชูŠุฑูˆุณูŠู†-ุชูŠุฑูˆุณูŠู† ุงู„ุญู„ู‚ูŠุฉ ูƒู…ุนุฏู„ุงุช ู„ู…ุณุชู‚ุจู„ุงุช ุงู„ุจุจุชูŠุฏ ุงู„ุนุตุจูŠ y
CN108299553B (zh) * 2017-01-13 2021-07-16 ๅš็‘ž็”Ÿ็‰ฉๅŒป่ฏ๏ผˆ่‹ๅทž๏ผ‰่‚กไปฝๆœ‰้™ๅ…ฌๅธ ่ƒƒๆณŒ้…ธ่ฐƒ่Š‚็ด ไฟฎ้ฅฐ็‰ฉ
KR102629006B1 (ko) 2017-03-23 2024-01-25 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์ธ์Š๋ฆฐ ์ˆ˜์šฉ์ฒด์™€์˜ ๊ฒฐํ•ฉ๋ ฅ์ด ๊ฐ์†Œ๋œ ์ธ์Š๋ฆฐ ์•„๋‚ ๋กœ๊ทธ์˜ ๊ฒฐํ•ฉ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
CN121591873A (zh) * 2018-07-19 2026-03-03 D&Dๅˆถ่ฏๆŠ€ๆœฏ่‚กไปฝๆœ‰้™ๅ…ฌๅธ ๅŒ…ๆ‹ฌๅคš่‚ฝ็š„่ฏ็‰ฉ็ป„ๅˆ็‰ฉ
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
EP3939990A4 (en) * 2019-02-15 2023-05-24 Hanmi Fine Chemical Co., Ltd. NOVEL INTERMEDIATE FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND PROCESS FOR THE PRODUCTION THEREOF
WO2021235915A1 (ko) 2020-05-22 2021-11-25 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์•ก์ƒ ์ œ์ œ
KR20210144606A (ko) * 2020-05-22 2021-11-30 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ๊ธ€๋ฃจ์นด๊ณค ์œ ๋„์ฒด์˜ ์ง€์†ํ˜• ๊ฒฐํ•ฉ์ฒด์˜ ์•ก์ƒ ์ œ์ œ

Citations (5)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100105494A (ko) * 2009-03-20 2010-09-29 ํ•œ๋ฏธํ™€๋”ฉ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์œ„์น˜ํŠน์ด์  ์ƒ๋ฆฌํ™œ์„ฑ ํด๋ฆฌํŽฉํƒ€์ด๋“œ ๊ฒฐํ•ฉ์ฒด์˜ ์ œ์กฐ๋ฐฉ๋ฒ•
CN102010473A (zh) * 2010-11-10 2011-04-13 ๆ›น้น ้‡็ป„่ƒƒๆณŒ้…ธ่ฐƒ่Š‚็ด ่žๅˆ่›‹็™ฝๅŠๅ…ถๅˆถๅค‡ๅ’Œๅบ”็”จ
WO2012011752A2 (en) * 2010-07-21 2012-01-26 Hanmi Holdings Co., Ltd. Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR20120043208A (ko) * 2010-10-26 2012-05-04 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ํ•ญ ๋น„๋งŒ ํŽฉํƒ€์ด๋“œ์˜ ์ง€์†ํ˜• ๊ฒฐํ•ฉ์ฒด
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate

Family Cites Families (78)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ใƒœใƒผใƒ‰ ใ‚ชใƒ– ใƒชใƒผใ‚ธใ‚งใƒณใƒ„๏ผŒใ‚ถ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒ†ใ‚ญใ‚ตใ‚น ใ‚ทใ‚นใƒ†ใƒ  ๅข—ๅคงใ—ใŸๅŠๆธ›ๆœŸใ‚’ๆœ‰ใ™ใ‚‹ๅ…็–ซใ‚ฐใƒญใƒ–ใƒชใƒณๆง˜ใƒ‰ใƒกใ‚คใƒณ
WO1999044630A1 (en) 1998-03-06 1999-09-10 Chugai Seiyaku Kabushiki Kaisha Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์ธ์Š๋ฆฐ ๋ถ„๋น„ ํŽฉํƒ€์ด๋“œ ๊ฒฐํ•ฉ์ฒด๋ฅผ ํฌํ•จํ•˜๋Š” ๋น„๋งŒ ๊ด€๋ จ์งˆํ™˜ ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2383300T3 (es) 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehรญculo de fรกrmacos y procedimiento para su preparaciรณn
CN101128487B (zh) 2004-12-02 2012-10-10 ๆœ้—จ่’‚ๆ–ฏๆœ‰้™ๅ…ฌๅธ ้ถๅ‘่ก€ๆธ…็™ฝ่›‹็™ฝๅ’Œglp-1ๆˆ–pyy็š„ๅŒ็‰นๅผ‚ๆ€ง็ป“ๆž„ๅŸŸๆŠ—ไฝ“
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
KR20070115947A (ko) 2005-02-11 2007-12-06 ์•„๋ฐ€๋ฆฐ ํŒŒ๋งˆ์Šˆํ‹ฐ์นผ์Šค, ์ธํฌ. ์„ ํƒ๊ฐ€๋Šฅํ•œ ํŠน์„ฑ๋“ค์„ ๊ฐ€์ง€๋Š” ๏ฝ‡๏ฝ‰๏ฝ ์œ ์‚ฌ์ฒด ๋ฐ ํ•˜์ด๋ธŒ๋ฆฌ๋“œํด๋ฆฌํŽฉํƒ€์ด๋“œ
KR100754667B1 (ko) 2005-04-08 2007-09-03 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ๋น„ํŽฉํƒ€์ด๋“œ์„ฑ ์ค‘ํ•ฉ์ฒด๋กœ ๊ฐœ์งˆ๋œ ๋ฉด์—ญ๊ธ€๋กœ๋ถˆ๋ฆฐ ๏ผฆ๏ฝƒ ๋‹จํŽธ ๋ฐ์ด๋ฅผ ํฌํ•จํ•˜๋Š” ์•ฝ์ œํ•™์  ์กฐ์„ฑ๋ฌผ
ATE553124T1 (de) 2005-06-13 2012-04-15 Imp Innovations Ltd Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd ๆ–ฐ็ฉŽๅŒ–ๅˆ็‰ฉๅŠๅ…ถ็ญ‰ๅฐ้€ฒ้ฃŸ่กŒ็‚บๅฝฑ้Ÿฟ
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd ใ‚ญใƒฃใƒชใ‚ข็‰ฉ่ณชใ‚’็”จใ„ใŸใ‚คใƒณใ‚นใƒชใƒณๅˆ†ๆณŒใƒšใƒ—ใƒใƒ‰่–ฌ็‰ฉ็ตๅˆไฝ“
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
ATE499088T1 (de) 2007-07-10 2011-03-15 Lilly Co Eli Glp-1-fc fusionsprotein-formulierung
CN103416421B (zh) 2007-07-27 2016-07-27 ๆ‹œๅฐ”ๅ†œไฝœ็‰ฉ็ง‘ๅญฆ่‚กไปฝๅ…ฌๅธ ไธ‰ๅ…ƒๆดปๆ€งๅŒ–ๅˆ็‰ฉ็ป“ๅˆ็‰ฉ
WO2009033739A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
JP2011503000A (ja) 2007-11-02 2011-01-27 ใ‚ปใƒณใƒˆใ‚ณใ‚ขใƒปใ‚ชใƒผใ‚ฝใƒปใƒใ‚คใ‚ชใƒ†ใƒ„ใ‚ฏใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒ„ใƒ‰ ๅŠๅˆๆˆ๏ผง๏ผฌ๏ผฐโˆ’๏ผ‘ใƒšใƒ—ใƒใƒ‰โˆ’๏ผฆ๏ฝƒ่žๅˆใ‚ณใƒณใ‚นใƒˆใƒฉใ‚ฏใƒˆใ€ใใฎๆ–นๆณ•ๅŠใณไฝฟ็”จ
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
JP5635531B2 (ja) 2008-12-15 2014-12-03 ใ‚ธใƒผใƒฉใƒณใƒ‰ ใƒ•ใ‚กใƒผใƒž ใ‚ขใ‚ฏใƒ†ใ‚ฃใƒผใ‚ผใƒซใ‚นใ‚ซใƒ– ใ‚ฐใƒซใ‚ซใ‚ดใƒณ้กžไผผไฝ“
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
CA2755336C (en) * 2009-03-20 2015-07-14 Amgen Inc. Carrier immunoglobulins and uses thereof
EP2443146B1 (en) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
JO2976B1 (en) 2009-12-22 2016-03-15 ุงูŠู„ูŠ ู„ูŠู„ูŠ ุงู†ุฏ ูƒูˆู…ุจุงู†ูŠ Axentomodulin polypeptide
KR20120123443A (ko) 2010-01-27 2012-11-08 ์ธ๋””์• ๋‚˜ ์œ ๋‹ˆ๋ฒ„์‹œํ‹ฐ ๋ฆฌ์„œ์น˜ ์•ค๋“œ ํ…Œํฌ๋†€๋กœ์ง€ ์ฝ”ํผ๋ ˆ์ด์…˜ ๋Œ€์‚ฌ ์žฅ์•  ๋ฐ ๋น„๋งŒ ์น˜๋ฃŒ์šฉ ๊ธ€๋ฃจ์นด๊ณค ๊ธธํ•ญ์ œ-๏ฝ‡๏ฝ‰๏ฝ ํ•ญ์ง„์ œ ์ฝ˜์ฅฌ๊ฒŒ์ดํŠธ
EP2552951A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
JP6050746B2 (ja) 2010-05-13 2016-12-21 ใ‚คใƒณใƒ‡ใ‚ฃใ‚ขใƒŠ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃใƒผ ใƒชใ‚ตใƒผใƒ ใ‚ขใƒณใƒ‰ ใƒ†ใ‚ฏใƒŽใƒญใ‚ธใƒผ ใ‚ณใƒผใƒใƒฌใƒผใ‚ทใƒงใƒณIndiana University Research And Technology Corporation ๏ผงใ‚ฟใƒณใƒ‘ใ‚ฏ่ณชๅ…ฑๅฝนๅ—ๅฎนไฝ“ๆดปๆ€งใ‚’็คบใ™ใ‚ฐใƒซใ‚ซใ‚ดใƒณใ‚นใƒผใƒ‘ใƒผใƒ•ใ‚กใƒŸใƒชใƒผใฎใƒšใƒ—ใƒใƒ‰
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
KR101314865B1 (ko) * 2010-07-06 2013-10-04 ๊น€๋•์ค‘ ๋ชจ๋ฐ”์ผ ํ™˜๊ฒฝ์—์„œ ๏ฝ”๏ฝ– ํ™”๋ฉด๊ณผ ์—ฐ๋™ํ•˜๋Š” ์ฆ๊ฐ• ํ˜„์‹ค์„ ์ œ๊ณตํ•˜๋Š” ๋ฐฉ๋ฒ•, ์ด๋ฅผ ์œ„ํ•œ ๋ถ€๊ฐ€ ์„œ๋น„์Šค ์„œ๋ฒ„ ๋ฐ ๋ฐฉ์†ก ์‹œ์Šคํ…œ
KR101337797B1 (ko) * 2010-07-14 2013-12-06 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์ง€์†ํ˜• ์ธ๊ฐ„ ์„ฑ์žฅ ํ˜ธ๋ฅด๋ชฌ ๊ฒฐํ•ฉ์ฒด ์•ก์ƒ ์ œ์ œ
CN102576513B (zh) 2010-09-06 2014-11-12 ๆพไธ‹็”ตๅ™จไบงไธšๆ ชๅผไผš็คพ ๆ˜พ็คบ่ฃ…็ฝฎๅŠๅ…ถๆŽงๅˆถๆ–นๆณ•
CN101974077A (zh) 2010-09-15 2011-02-16 ๅ—ไบฌ็‘žๅนดๅคฉๅนณๅŒป่ฏ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็งๆ–ฐ้ข–็š„ๅคš่‚ฝๅŒ–ๅˆ็‰ฉ
KR101303388B1 (ko) * 2010-10-26 2013-09-03 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์ง€์†ํ˜• ์ธํ„ฐํŽ˜๋ก  ์•ŒํŒŒ ๊ฒฐํ•ฉ์ฒด์˜ ์•ก์ƒ ์ œ์ œ
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP6118500B2 (ja) 2011-02-28 2017-04-19 ใƒญใƒผใƒ  ใ‚ขใƒณใƒ‰ ใƒใƒผใ‚น ใ‚จใƒฌใ‚ฏใƒˆใƒญใƒ‹ใƒƒใ‚ฏ ใƒžใƒ†ใƒชใ‚ขใƒซใ‚บ ใ‚จใƒซใ‚จใƒซใ‚ทใƒผ๏ผฒ๏ฝ๏ฝˆ๏ฝ ๏ฝ๏ฝŽ๏ฝ„ ๏ผจ๏ฝ๏ฝ๏ฝ“ ๏ผฅ๏ฝŒ๏ฝ…๏ฝƒ๏ฝ”๏ฝ’๏ฝ๏ฝŽ๏ฝ‰๏ฝƒ ๏ผญ๏ฝ๏ฝ”๏ฝ…๏ฝ’๏ฝ‰๏ฝ๏ฝŒ๏ฝ“ ๏ผฌ๏ผฌ๏ผฃ ใƒ•ใ‚ฉใƒˆใƒฌใ‚ธใ‚นใƒˆ็ต„ๆˆ็‰ฉใ€ใŠใ‚ˆใณใƒ•ใ‚ฉใƒˆใƒชใ‚ฝใ‚ฐใƒฉใƒ•ใ‚ฃใƒ‘ใ‚ฟใƒผใƒณใ‚’ๅฝขๆˆใ™ใ‚‹ๆ–นๆณ•
KR101161526B1 (ko) 2011-05-16 2012-07-02 ์ˆญ์‹ค๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์—ฐ๋ฃŒ์ „์ง€์šฉ ์ด‰๋งค์ „๊ทน์„ ์œ„ํ•œ ์ฝ”์–ด/์‰˜ ๊ตฌ์กฐ์˜ ๋‚˜๋…ธ ์ง€์ง€์ฒด ๋ฐ ๊ทธ ์ œ์กฐ๋ฐฉ๋ฒ•
UA126465C2 (uk) 2011-06-10 2022-10-12 ะฅะฐะฝะผั– ะกะฐะนะตะฝั ะšะพ., ะ›ั‚ะด. ะŸะตะฟั‚ะธะด, ั‰ะพ ะผะฐั” ะฐะบั‚ะธะฒะฝั–ัั‚ัŒ ะพะบัะธะฝั‚ะพะผะพะดัƒะปั–ะฝัƒ, ั‚ะฐ ั„ะฐั€ะผะฐั†ะตะฒั‚ะธั‡ะฝะฐ ะบะพะผะฟะพะทะธั†ั–ั ะดะปั ะปั–ะบัƒะฒะฐะฝะฝั ะพะถะธั€ั–ะฝะฝั, ัะบะฐ ะนะพะณะพ ะผั–ัั‚ะธั‚ัŒ
RU2607365C2 (ru) 2011-06-17 2017-01-10 ะฅะฐะฝะผะธ ะกะฐะนะตะฝั ะšะพ., ะ›ั‚ะด. ะšะพะฝัŠัŽะณะฐั‚, ัะพะดะตั€ะถะฐั‰ะธะน ะพะบัะธะฝั‚ะพะผะพะดัƒะปะธะฝ ะธ ั„ั€ะฐะณะผะตะฝั‚ ะธะผะผัƒะฝะพะณะปะพะฑัƒะปะธะฝะฐ, ะธ ะตะณะพ ะฟั€ะธะผะตะฝะตะฝะธะต
KR20140043793A (ko) * 2011-06-22 2014-04-10 ์ธ๋””์• ๋‚˜ ์œ ๋‹ˆ๋ฒ„์‹œํ‹ฐ ๋ฆฌ์„œ์น˜ ์•ค๋“œ ํ…Œํฌ๋†€๋กœ์ง€ ์ฝ”ํผ๋ ˆ์ด์…˜ ๊ธ€๋ฃจ์นด๊ณค/glp-1 ์ˆ˜์šฉ์ฒด ๊ณต๋™-์ž‘์šฉ๋ฌผ์งˆ
KR101665009B1 (ko) 2012-03-09 2016-10-11 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ๋น„์•Œ์ฝœ์„ฑ ์ง€๋ฐฉ๊ฐ„ ์งˆํ™˜์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์•ฝํ•™์  ์กฐ์„ฑ๋ฌผ
HK1207564A1 (en) 2012-04-19 2016-02-05 Opko Biologics Ltd Long-acting oxyntomodulin variants and methods of producing same
CN104583232B (zh) 2012-06-21 2018-04-13 ๅฐ็ฌฌๅฎ‰็บณๅคงๅญฆ็ ”็ฉถๅŠ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ๅฑ•็Žฐgipๅ—ไฝ“ๆดปๆ€ง็š„่ƒฐ้ซ˜่ก€็ณ–็ด ็ฑปไผผ็‰ฉ
KR101373563B1 (ko) 2012-07-25 2014-03-12 ์ „๋ถ๋Œ€ํ•™๊ต์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ๏ผด๏ฝ๏ฝ†-๏ฝ๏ฝ’๏ฝ๋ฅผ ์ด์šฉํ•œ ํ˜ˆ๋ฅ˜ํŠน์„ฑ ๋ฐ ๏ฝ๏ฝ’-์‹ ํ˜ธ๊ฐ•๋„๊ตฌ๋ฐฐ(์ „๋‹จ์œจ) ์œ ๋„๋ฐฉ๋ฒ•
KR101968344B1 (ko) 2012-07-25 2019-04-12 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์˜ฅ์‹ ํ† ๋ชจ๋“ˆ๋ฆฐ ์œ ๋„์ฒด๋ฅผ ํฌํ•จํ•˜๋Š” ๊ณ ์ง€ํ˜ˆ์ฆ ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 ํ•œ๋ฏธ์•ฝํ’ˆ ์ฃผ์‹ํšŒ์‚ฌ ์˜ฅ์‹ ํ† ๋ชจ๋“ˆ๋ฆฐ ์œ ๋„์ฒด๋ฅผ ํฌํ•จํ•˜๋Š” ๋‹น๋‡จ๋ณ‘ ๋˜๋Š” ๋น„๋งŒ์„ฑ ๋‹น๋‡จ๋ณ‘ ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
WO2014073842A1 (en) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
JP6137046B2 (ja) 2014-05-09 2017-05-31 ไฟก่ถŠๅŒ–ๅญฆๅทฅๆฅญๆ ชๅผไผš็คพ ๅ˜้‡ไฝ“ใ€้ซ˜ๅˆ†ๅญๅŒ–ๅˆ็‰ฉใ€ใƒฌใ‚ธใ‚นใƒˆๆๆ–™ๅŠใณใƒ‘ใ‚ฟใƒผใƒณๅฝขๆˆๆ–นๆณ•
TWI802396B (zh) 2014-09-16 2023-05-11 ๅ—้Ÿ“ๅ•†้Ÿ“็พŽ่—ฅๅ“่‚กไปฝๆœ‰้™ๅ…ฌๅธ ้•ทๆ•ˆglp-1/้ซ˜่ก€็ณ–็ด ๅ—้ซ”้›™ไฟƒๆ•ˆๅŠ‘ๆฒป็™‚้ž้…’็ฒพๆ€ง่„‚่‚็–พ็—…ไน‹็”จ้€”
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Patent Citations (5)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR20100105494A (ko) * 2009-03-20 2010-09-29 ํ•œ๋ฏธํ™€๋”ฉ์Šค ์ฃผ์‹ํšŒ์‚ฌ ์œ„์น˜ํŠน์ด์  ์ƒ๋ฆฌํ™œ์„ฑ ํด๋ฆฌํŽฉํƒ€์ด๋“œ ๊ฒฐํ•ฉ์ฒด์˜ ์ œ์กฐ๋ฐฉ๋ฒ•
WO2012011752A2 (en) * 2010-07-21 2012-01-26 Hanmi Holdings Co., Ltd. Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR20120043208A (ko) * 2010-10-26 2012-05-04 ํ•œ๋ฏธ์‚ฌ์ด์–ธ์Šค ์ฃผ์‹ํšŒ์‚ฌ ํ•ญ ๋น„๋งŒ ํŽฉํƒ€์ด๋“œ์˜ ์ง€์†ํ˜• ๊ฒฐํ•ฉ์ฒด
CN102010473A (zh) * 2010-11-10 2011-04-13 ๆ›น้น ้‡็ป„่ƒƒๆณŒ้…ธ่ฐƒ่Š‚็ด ่žๅˆ่›‹็™ฝๅŠๅ…ถๅˆถๅค‡ๅ’Œๅบ”็”จ

Also Published As

Publication number Publication date
CA2890324A1 (en) 2014-05-15
EA201992760A3 (ru) 2020-06-30
EA034499B1 (ru) 2020-02-13
CA2890324C (en) 2021-02-23
MX2015005698A (es) 2015-08-20
SG11201503370WA (en) 2015-05-28
US20150290324A1 (en) 2015-10-15
KR102311517B1 (ko) 2021-10-14
TW201919585A (zh) 2019-06-01
ZA201503998B (en) 2016-09-28
TW201427716A (zh) 2014-07-16
EA031852B1 (ru) 2019-03-29
US11071785B2 (en) 2021-07-27
EA039082B1 (ru) 2021-12-01
EA201791143A1 (ru) 2017-11-30
EP3610856A1 (en) 2020-02-19
PH12015501008B1 (en) 2019-02-06
EP2916819B1 (en) 2019-07-10
EP2916819A4 (en) 2016-08-17
PH12015501008A1 (en) 2015-07-27
MY197849A (en) 2023-07-20
HK1210044A1 (en) 2016-04-15
AU2013342321A1 (en) 2015-05-28
NZ731658A (en) 2020-05-29
IL238626A0 (en) 2015-06-30
IL238626B (en) 2019-02-28
KR20210125453A (ko) 2021-10-18
CN104884045B (zh) 2018-06-15
EP3610856B1 (en) 2021-08-18
TWI602583B (zh) 2017-10-21
MY168536A (en) 2018-11-12
PE20151421A1 (es) 2015-09-24
PL2916819T3 (pl) 2020-01-31
WO2014073842A1 (en) 2014-05-15
UA126651C2 (uk) 2023-01-11
IL264360B (en) 2019-11-28
AU2020200626B2 (en) 2022-02-10
US9724420B2 (en) 2017-08-08
TWI652071B (zh) 2019-03-01
JP6363612B2 (ja) 2018-07-25
CL2015001206A1 (es) 2015-07-03
EA201992760A2 (ru) 2020-03-31
JP2018162299A (ja) 2018-10-18
TW201740924A (zh) 2017-12-01
IL264360A (en) 2019-02-28
AU2020200626A1 (en) 2020-02-20
BR112015010235B1 (pt) 2021-05-18
ES2748158T3 (es) 2020-03-13
UA116364C2 (uk) 2018-03-12
US10279041B2 (en) 2019-05-07
CN104884045A (zh) 2015-09-02
AU2017279583B2 (en) 2019-11-21
DK2916819T3 (da) 2019-10-14
PT2916819T (pt) 2019-10-28
KR102434280B1 (ko) 2022-08-23
US20190269779A1 (en) 2019-09-05
AR121939A2 (es) 2022-07-27
SG10201602801YA (en) 2016-05-30
AR093387A1 (es) 2015-06-03
EA201590758A1 (ru) 2015-10-30
EP2916819A1 (en) 2015-09-16
TWI816739B (zh) 2023-10-01
BR112015010235A2 (pt) 2017-08-22
NZ739063A (en) 2019-11-29
AU2017279583A1 (en) 2018-01-18
JP6694013B2 (ja) 2020-05-13
JP2015536942A (ja) 2015-12-24
NZ708103A (en) 2018-07-27
KR20140058387A (ko) 2014-05-14
PH12018501454A1 (en) 2020-02-17
US20170360939A1 (en) 2017-12-21
MX372833B (es) 2020-06-25
MX2020004114A (es) 2020-07-24

Similar Documents

Publication Publication Date Title
US11071785B2 (en) Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
EP4154868A1 (en) Liquid formulation of long-acting conjugate of glucagon derivative
HK40023221A (en) Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
HK40023221B (en) Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
HK1210044B (zh) ๅŒ…ๆ‹ฌ่ƒƒๆณŒ้…ธ่ฐƒ่Š‚็ด ๅ’Œๅ…็–ซ็ƒ่›‹็™ฝ็‰‡ๆฎต็š„่›‹็™ฝ่ดจ็ผ€ๅˆ็‰ฉ็š„ๆถฒไฝ“ๅˆถๅ‰‚
NZ742400B2 (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)